

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Grand Pharmaceutical Group Limited

遠大醫藥集團有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00512)

PROPOSED ADOPTION OF NEW BYE-LAWS

This announcement is made by Grand Pharmaceutical Group Limited (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors (the “**Board**”) of the Company proposes to make certain amendments to the bye-laws of the Company currently in force (the “**Existing Bye-laws**”), (i) align the Existing Bye-laws with the expanded paperless listing regime, the electronic dissemination of corporate communications by listed issuers, and the new treasury shares regime under the Listing Rules, and to facilitate the implementation of an uncertificated securities market; and (ii) making other housekeeping amendments, including consequential amendments in line with the above amendments to the Existing Bye-laws (collectively, the “**Proposed Amendments**”).

The Board proposes to adopt a new set of bye-laws incorporating and consolidating the Proposed Amendments in substitution for, and to the exclusion of, the Existing Bye-laws, which will be subject to the approval of the shareholders of the Company (“**Shareholders**”) by way of a special resolution to be proposed at the annual general meeting of the Company to be held on 5 June 2026 (the “**AGM**”).

A circular containing, among other things, details of the Proposed Amendments together with a notice convening the AGM will be despatched to the Shareholders in due course.

By order of the Board
Grand Pharmaceutical Group Limited
Chairman
Dr. Tang Weikun

Hong Kong, 30 April 2026

As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Mr. Zhou Chao, Mr. Yang Guang and Ms. Lam Chit Yee Jessica, and four independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Xing Li Na, Dr. Pei Geng and Mr. Hu Yebi.

** For identification purpose only*